Location: Zoom

Dec 10 2021

Alterations of glycosylation are common molecular alterations with major biological implications for cancer progression. Cancer is a heterogeneous disease that requires multidisciplinary treatment. Current targeted therapy depends on patient stratification based on molecular features of the tumour. This presentation will report on the basis of alterations of glycosylation that occur in cancer.

Recent results applying glycomic and glycoproteomic strategies in human cancer provided novel information with major clinical implications. This presentation will report on the alterations of glycosylation impact the activation of oncogenic receptors in tumour samples, advanced cell and tissue models, including the recently described glycoproteomic map of the HER2 (ErbB2) in gastric cancer cells. Glycomic and glycoproteomic analysis of HER2 disclosed a site-specific glycosylation profile in gastric cancer cells. HER2-specific glycosylation affects the receptor and the sensitivity of HER2-dependent gastric cancer cells to trastuzumab-induced cytotoxicity.

These results disclose novel functional aspects of glycosylation modifications occurring in cancer and highlight their potential for patient stratification, personalized medicine, and novel and improved therapeutic applications.

For the link to the webinar click here.

Latest Press Releases